Press releases

Press releases

12 April 2014  - Paris (France)

Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul

11 April 2014  - Paris (France)

The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, "Biology viewed through the prism of cancer", attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research

09 April 2014  - Paris (France)

Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext

20 March 2014  - Paris (France)

Ipsen announces that its controlling shareholder, Mayroy, sold approximately 7% of Ipsen’s share capital via private placement

18 March 2014  - Paris (France)

Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO)

28 February 2014  - Paris (France)

Ipsen’s 2013 results and 2014 financial objectives

07 February 2014  - Paris (France)

Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer

05 February 2014  - Paris (France)

Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW

28 January 2014  - Paris (France)

Ipsen: sales in the fourth quarter and full year 2013

22 January 2014  - Paris (France)

Ipsen implements a new governance in the United States to prepare for the launch of Somatuline® in oncology